A promising new vaccination technique for long-term treatment was successfully tested in two mouse models of AD: Cells that continuously secreted β-amyloid antibodies for more than 10 months were implanted subcutaneously before an actual plaque accumulation and dramatically reduced amyloid and tau pathologies21,25. This evidence concerns the gene MAPT and Alzheimer disease.